Christophe dombu
Stock Analyst at Kepler Capital
(0.15)
# 4,724
Out of 5,099 analysts
98
Total ratings
41.2%
Success rate
-10.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christophe dombu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNN Smith & Nephew | Downgraded: Hold | n/a | $30.17 | - | 1 | Jun 4, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Reiterated: Sell | €23.50 | €28.72 | -18.18% | 19 | May 7, 2026 | |
| LON: SN Smith & Nephew plc | Reiterated: Buy | 1,462p | 1,118p | +30.83% | 5 | May 6, 2026 | |
| EPA: VIRP Virbac SA | Reiterated: Buy | €415.00 | €354.50 | +17.07% | 6 | Apr 17, 2026 | |
| SWX: KURN Kuros Biosciences AG | Reiterated: Buy | CHF 38.00 | CHF 20.26 | +87.56% | 9 | Apr 14, 2026 | |
| SWX: BSLN Basilea Pharmaceutica AG | Reiterated: Buy | CHF 69.00 → CHF 70.00 | CHF 73.00 | -4.11% | 27 | Apr 13, 2026 | |
| EPA: MAAT MaaT Pharma SA | Reiterated: Buy | €17.00 | €1.02 | +1,573.23% | 26 | Mar 31, 2026 | |
| EPA: ALVIO Valerio Therapeutics Société anonyme | Downgraded: Sell | €0.10 → €0.01 | €0.42 | n/a | 5 | Feb 7, 2025 |
Smith & Nephew
Jun 4, 2026
Downgraded: Hold
Price Target: n/a
Current: $30.17
Upside: -
Lakefront Biotherapeutics NV
May 7, 2026
Reiterated: Sell
Price Target: €23.50
Current: €28.72
Upside: -18.18%
Smith & Nephew plc
May 6, 2026
Reiterated: Buy
Price Target: 1,462p
Current: 1,118p
Upside: +30.83%
Virbac SA
Apr 17, 2026
Reiterated: Buy
Price Target: €415.00
Current: €354.50
Upside: +17.07%
Kuros Biosciences AG
Apr 14, 2026
Reiterated: Buy
Price Target: CHF 38.00
Current: CHF 20.26
Upside: +87.56%
Basilea Pharmaceutica AG
Apr 13, 2026
Reiterated: Buy
Price Target: CHF 69.00 → CHF 70.00
Current: CHF 73.00
Upside: -4.11%
MaaT Pharma SA
Mar 31, 2026
Reiterated: Buy
Price Target: €17.00
Current: €1.02
Upside: +1,573.23%
Valerio Therapeutics Société anonyme
Feb 7, 2025
Downgraded: Sell
Price Target: €0.10 → €0.01
Current: €0.42
Upside: n/a